Journal
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
Volume 58, Issue 3, Pages 341-352Publisher
WILEY
DOI: 10.1111/1754-9485.12163
Keywords
chemoembolisation; hepatic metastasis; radioembolisation; yttrium-90 microspheres
Funding
- Sirtex Medical Ltd, Sydney, Australia
Ask authors/readers for more resources
Liver-directed therapies are continuing to evolve in the field of interventional oncology and are gaining increasing use in the treatment of unresectable primary and secondary liver cancers. In this article, we review two liver-directed therapies that are currently used for the palliative treatment of primary and secondary hepatic tumours: transcatheter arterial chemoembolisation (TACE), including a new type of TACE with drug-eluting beads (DEB-TACE), and radioembolisation. The concept of these transcatheter intraarterial therapies is to selectively deliver high doses of anticancer treatment to the tumour. While TACE delivers one or more chemotherapeutic drugs into the hepatic arteries supplying the tumour, radioembolisation uses non-embolic microspheres incorporating the radioactive isotope 90Y. In this article, we discuss some technical aspects, patient selection, current clinical evidence, and future directions of TACE, TACE with drug-eluting beads (DEB-TACE) and radioembolisation for primary and secondary liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available